Douglas Maready, MD
Internal Medicine · Mesa, AZNPI 1689876252
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intra-sana Laboratories at 54.5% of the total. 2025 is the largest year on record at $7,396, more than ten times the $540 reported in 2019. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $43.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intra-sana Laboratories$7K
- Novo Nordisk$2K
- Lilly USA, LLC$629
- Amgen$483
- Corcept Therapeutics$451
- Boehringer Ingelheim$270
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$6,00049%
- Food & beverage$5,84548%
- Education$3613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intra-sana Laboratories | 49 | $6,646 |
| Novo Nordisk | 61 | $1,975 |
| Lilly USA, LLC | 40 | $629 |
| Amgen | 20 | $483 |
| Corcept Therapeutics | 19 | $451 |
| Boehringer Ingelheim | 14 | $270 |
| Abbott | 12 | $218 |
| Inspire Medical Systems, Inc. | 2 | $164 |
| Exact Sciences | 5 | $158 |
| AbbVie | 7 | $152 |
| Rhythm Pharmaceuticals, Inc. | 4 | $147 |
| Vivus LLC | 1 | $120 |
| Pfizer | 6 | $107 |
| Currax Pharmaceuticals LLC | 7 | $106 |
| Astellas Pharma US Inc | 4 | $75 |
| GSK | 4 | $64 |
| Boston Scientific | 3 | $59 |
| Nevro Corp. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Nalu Medical, Inc. | 2 | $37 |
| Tactile Systems Technology Inc | 1 | $37 |
| Bayer | 2 | $31 |
| Impulse Dynamics (USA) Inc. | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Viiv Healthcare Company | 1 | $29 |
| Novartis | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Biomerieux Inc | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$5,786
- GLYCATE$5,786
- Reltone 400 Mg$5,786
- Wegovy$237
- Inspire$138
- QSYMIA$120
How this compares
$12,205 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $275,331 |
| OzempicSemaglutide | 85 | $160,812 |
| JardianceEmpagliflozin | 84 | $99,246 |
| MounjaroTirzepatide | 43 | $52,048 |
| WegovySemaglutide | 20 | $27,174 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $23,834 |
| EliquisApixaban | 15 | $22,446 |
| XareltoRivaroxaban | 14 | $18,954 |
| Repatha SureclickEvolocumab | 11 | $17,676 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 53 | $16,559 |
| TrulicityDulaglutide | 16 | $15,816 |
| MyrbetriqMirabegron | 15 | $10,958 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,547 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 38 | $8,513 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $451 | $275,33111 claims |
| Novo NordiskOzempic, Wegovy | $1,975 | $187,987105 claims |
| Boehringer IngelheimJardiance | $270 | $99,24684 claims |
| Lilly USA, LLCMounjaro, Trulicity | $629 | $67,86359 claims |
| GSKArexvy, Shingrix, Breo Ellipta | $64 | $33,144105 claims |
| PfizerEliquis | $107 | $22,44615 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $10,95815 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,812183 claims |
| AbbVieSynthroid | $152 | $83222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Mesa
- Mathew BenjaminMesa$17K
- Thanh NguyenMesa$16K
- Tami BruceMesa$12K
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Rajesh JanardhananTucson$685K
- Mona SelejTucson$440K
- Kelly KrohnPhoenix$262K
- Jacque SokolovScottsdale$235K
- Paul StanderPhoenix$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.